MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2014.59.3673

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015

Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.

He Wei, Fang Fang, Varnum Catherine, Eriksson Mikael, Hall Per, Czene Kamila

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: To identify predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer.

PATIENTS AND

METHODS

We conducted a record-linkage study based on data from Stockholm-Gotland Breast Cancer Register, Swedish Prescribed Drug Register, and self-reported questionnaire. Women diagnosed with breast cancer between 2005 and 2008 in Stockholm, Sweden, were prospectively followed for 5 years until 2013, starting from their first prescription of tamoxifen or aromatase inhibitors (N = 3,395).

RESULTS

Family history of ovarian cancer (hazard ratio [HR], 1.55; 95% CI, 1.19 to 2.02); younger (< 40 years; HR, 1.39; 95% CI, 1.08 to 1.78) and older (≥ 65 years; HR, 1.15; 95% CI, 1.03 to 1.28) age; higher Charlson comorbidity index (≥ 2 v 0; HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI drugs (HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1.49) were identified as baseline predictors for hormonal treatment discontinuation. Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), antidepressants (HR, 1.22; 95% CI, 1.06 to 1.40), or GI drugs (HR, 1.27; 95% CI, 1.13 to 1.43), and switching therapy between tamoxifen and aromatase inhibitors (HR, 1.50; 95% CI, 1.23 to 1.83) during the first year of hormonal treatment were associated with increased risk of discontinuation during the next 4 years.

CONCLUSION

Predictors identified in our study can be used in developing targeted intervention to prevent adjuvant hormone therapy discontinuation and subsequently to improve breast cancer outcomes.

Для цитирования: He Wei, Fang Fang, Varnum Catherine, Eriksson Mikael, Hall Per, Czene Kamila. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. DOI: 10.1200/jco.2014.59.3673.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.